Antiangiogenic Herbal Composition Ob-X Reduces Abdominal Visceral Fat in Humans: A Randomized, Double-Blind, Placebo-Controlled Study

Figure 3

Reduction in visceral fat after 12-week treatment of Ob-X. (a) Visceral fat area was analyzed by computed tomography ( < 0.05 compared with placebo). (b) Representative CT-scan data at 0 and 12 weeks in a subject from Ob-X or placebo group. Differences in abdominal visceral fat (AVF), abdominal subcutaneous fat (ASF), and total abdominal fat (ATF) areas at 0 and 12 weeks were measured. Computed tomography scanning for measuring fat area was performed with subject in the supine position, at the lumbar vertebra 4 level. Visceral fat area of the patient before and after Ob-X treatment was represented by the green color. Values represent the mean ± SD.

(a)

(b)